CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed “minimal residual disease”. The phenomenon of disease persistence sugges...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinstrie, Ross, Horne, Gillian A., Morrison, Heather, Irvine, David, Munje, Chinmay, Castañeda, Eduardo Gómez, Moka, Hothri A., Dunn, Karen, Cassels, Jennifer E., Parry, Narissa, Clarke, Cassie J., Scott, Mary T., Clark, Richard E., Holyoake, Tessa L., Wheadon, Helen, Copland, Mhairi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272220/
https://www.ncbi.nlm.nih.gov/pubmed/31896780
http://dx.doi.org/10.1038/s41375-019-0684-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272220/
https://www.ncbi.nlm.nih.gov/pubmed/31896780
http://dx.doi.org/10.1038/s41375-019-0684-5

Ejemplares similares